文献速递呼吸道感染呼吸危重症与机械通气

利用床旁生命体征轨迹识别COVID-19亚表型

Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes.
PubMed 文献 · Chest · 2023-09-23

本研究在Emory医疗系统四家学术医院纳入2020年3月1日至2022年5月31日住院的成年COVID-19患者,用经验证的基于组的轨迹模型,依据入院前8小时口服温度、心率、呼吸频率及收缩压和舒张压将患者分为四个亚表型,比较临床特征、生物标志物和结局,并评估托珠单抗治疗效应的异质性。

要点

  • 四个亚表型中A组和D组的机械通气、血管升压药使用及30天住院死亡OR更高(P < .001)。
  • 亚表型间托珠单抗与30天死亡率的关联存在显著治疗效应异质性(P = .001)。
  • 床旁生命体征轨迹可在低资源环境识别COVID-19亚表型。

核心结论

  • 利用床旁生命体征轨迹可识别与COVID-19不同临床表现相关的亚表型,可能有助于抢先和靶向治疗。

研究设计与样本

  • 多中心队列研究,纳入Emory医疗系统四家学术医院2020年3月1日至2022年5月31日住院的成年COVID-19患者,共7,065例。
  • 使用经验证的基于组的轨迹模型,依据入院前8小时口服温度、心率、呼吸频率及收缩压和舒张压进行分类。

主要发现

  • A组(n = 1,429,20%)为高体温、心率、呼吸频率且低血压;B组(1,454,21%)为高体温、心率、呼吸频率且高血压;C组(2,996,42%)为低体温、心率、呼吸频率且血压正常;D组(1,186,17%)为低体温、心率、呼吸频率且低血压。
  • A组和D组机械通气、血管升压药使用及30天住院死亡的OR更高(P < .001)。
  • 比较接受托珠单抗患者(n = 55)与符合托珠单抗标准但在其使用前入院患者(n = 461),托珠单抗与30天死亡率关联在各亚表型间存在显著治疗效应异质性(P = .001)。

临床怎么用

  • 可利用入院早期床旁生命体征轨迹对COVID-19患者进行亚表型分类,辅助识别高危患者并评估治疗效应异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trajectories of bedside vital signs have been used to identify sepsis subphenotypes with distinct outcomes and treatment responses. The objective of this study was to validate the vitals trajectory model in a multicenter cohort of patients hospitalized with COVID-19 and to evaluate the clinical characteristics and outcomes of the resulting subphenotypes. RESEARCH QUESTION: Can the trajectory of routine bedside vital signs identify COVID-19 subphenotypes with distinct clinical characteristics and outcomes? STUDY DESIGN AND METHODS: The study included adult patients admitted with COVID-19 to four academic hospitals in the Emory Healthcare system between March 1, 2020, and May 31, 2022. Using a validated group-based trajectory model, we classified patients into previously defined vital sign trajectories using oral temperature, heart rate, respiratory rate, and systolic and diastolic BP measured in the first 8 h of hospitalization. Clinical characteristics, biomarkers, and outcomes were compared between subphenotypes. Heterogeneity of treatment effect to tocilizumab was evaluated. RESULTS: The 7,065 patients with hospitalized COVID-19 were classified into four subphenotypes: group A (n = 1,429, 20%)-high temperature, heart rate, respiratory rate, and hypotensive; group B (1,454, 21%)-high temperature, heart rate, respiratory rate, and hypertensive; group C (2,996, 42%)-low temperature, heart rate, respiratory rate, and normotensive; and group D (1,186, 17%)-low temperature, heart rate, respiratory rate, and hypotensive. Groups A and D had higher ORs of mechanical ventilation, vasopressors, and 30-day inpatient mortality (P < .001). On comparing patients receiving tocilizumab (n = 55) with those who met criteria for tocilizumab but were admitted before its use (n = 461), there was significant heterogeneity of treatment effect across subphenotypes in the association of tocilizumab with 30-day mortality (P = .001). INTERPRETATION: By using bedside vital signs available in even low-resource settings, we found novel subphenotypes associated with distinct manifestations of COVID-19, which could lead to preemptive and targeted treatments.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Bhavani SV, Robichaux C, Verhoef PA, et al. Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes. Chest. 2023. PMID: 37748574. doi:10.1016/j.chest.2023.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。